Sandoz Pushes Further Into High-Barrier Generics With $1.5B Acquisition of Fougera
This article was originally published in The Pink Sheet Daily
Sandoz is acquiring the U.S. generics dermatology business Fougera, which formerly belonged to Nycomed, for $1.5 billion in cash, giving it entry into a highly profitable niche market.
You may also be interested in...
Sandoz + Fougera = 4 Topical Generics For Tolmar
FTC’s proposed consent agreement requires the Novartis unit to return marketing rights to calcipotriene topical solution, lidocaine-prilocaine cream and metronidazole topical gel to Tolmar Inc., as well as rights to market a future generic version of Solaraze (diclofenac sodium gel).
Nycomed US Crowns New Management; Plans New Direction
Now that Japan's Takeda Pharmaceuticals Co. Ltd. is just months away from closing on its €9.6 billion ($13.7 billion) purchase of privately-held Nycomed AS, the Swiss company's investors are planning plenty of changes for the U.S. dermatology business that wasn’t included in the large acquisition.
Takeda's $13.6 Bil. Nycomed Buy Meets Multiple Strategic, Financial Imperatives
Takeda Pharmaceuticals Co. Ltd.'s €9.6 billion ($13.6 billion) purchase of privately held Nycomed AS, confirmed May 19 after a week of speculation, satisfies a number of strategic and financial imperatives for Japan's largest drug maker, as it faces generic competition to best-selling diabetes drug Actos (pioglitazone) from 2012 and seeks to expand its footprint beyond Japan and the U.S.